Pharmaceuticals
WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
SHANGHAI, May 27, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Drug Product Facility 15 (DP15), located at the company's Fengxian site in Shanghai, achieved GMP release in April. The facil...
2026-05-27 17:14
7660
CordenPharma Acquires AmbioPharm to Expand Global Peptide API Capacity
Acquisition strengthens U.S. peptide manufacturing capabilities and broadens global expertise in complex peptide APIs * CordenPharma has entered into an agreement to acquire AmbioPharm, a U.S.-headquartered peptide CDMO with facilities in North Augusta, South Carolina (USA) and Shanghai (China...
2026-05-27 13:00
4972
Neurophet Launches Joint Study with VHIR on 'Neurophet AQUA MS', Accelerating AI Algorithm Validation
* Collaborative research on AI-based diagnosis of multiple sclerosis, Building a clinical trial dataset * Leveraging large-scale, multi-center brain MRI datasets to detect key lesion biomarkers SEOUL, South Korea, May 26, 2026 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon ...
2026-05-26 21:00
7580
Deepening Focus on Autoimmune Diseases, Empowering AI-Driven Drug Discovery
HkeyBio Builds a High-Efficiency Wet-Lab Validation Engine with Comprehensive CRO Service Upgrades in 2026 BOSTON and SUZHOU, China, May 26, 2026 /PRNewswire/ -- I. Industry Background: AI-Driven Drug Discovery Fuels Explosive Demand for Wet-Lab Validation, Creating New Opportunities for Specia...
2026-05-26 20:30
5265
SK bioscience Signs Vaccine Technology Transfer Agreement with Colombia's VECOL to Advance Local Vaccine Manufacturing in Latin America
* SK bioscience collaborates with Colombia's government-led US$260 million vaccine localization initiative through technology transfer and local manufacturing cooperation with state-owned pharmaceutical company VECOL * This alliance enables SK bioscience to enter Latin America by manufacturing...
2026-05-26 20:00
7654
Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine
* Approval granted by South Korea's Ministry of Food and Drug Safety (MFDS) * Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for the preventive treatment of migraine in adults * Authorization supported by the Phase 3 SUNRISE trial conducted in a predominant...
2026-05-26 14:38
5071
Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
* Data spans seven presentations across both solid tumors and hematologic malignancies, providing updates on the potential benefit these therapies may bring to patients. * Data from the elacestrant plus capivasertib regimen of the ELEVATE study will be presented underscoring its potential i...
2026-05-25 18:56
6707
Informa Markets Puts Bangkok at the Center of Southeast Asia's Pharma Industry, Uniting 400 Exhibitors, Experts from 70 Countries at CPHI South East Asia
The Region's Premier Pharma Exhibition Returns to Bangkok, Elevating Thailand's Role in the ASEAN Pharmaceutical Supply Chain BANGKOK, May 24, 2026 /PRNewswire/ -- Informa Markets sets to organise CPHI South East Asia from 8–10 July 2026 at Queen Sirikit National Convention Center under the them...
2026-05-24 13:00
5052
Meet Clicklinks: The Innovation Hub for Original Drug Discovery
SHANGHAI, May 23, 2026 /PRNewswire/ -- For many participants in the innovative drug discovery arena, AI-STAL and SAI-DA are already familiar names within the Sanyou Bio ecosystem. AI-STAL is recognized as the "Grand Master Librarian" safeguarding a Super Trillion Antibody Library, while SAI-DA is...
2026-05-23 22:00
5051
Mabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentations
SHANGHAI, May 21, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present multiple clinical study results of its novel Nectin-4-targeting ADC 9MW2821 (Bulumtatug Fuvedotin, BFv) at the 2026 American S...
2026-05-22 11:30
8430
Nuance Pharma Announces IND Clearance for Actair® Pivotal Clinical Trial in China
NMPA Approval Marks Key Milestone in Advancing House Dust Mite Allergy Immunotherapy to Chinese Patients SHANGHAI, May 22, 2026 /PRNewswire/ -- Nuance Pharma today announced that the National Medical Products Administration (NMPA) has cleared its Investigational New Drug (IND) application, enabl...
2026-05-22 09:50
4871
Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026
* Sacituzumab tirumotecan (sac-TMT)(佳泰莱®) plus pembrolizumab versus pembrolizumab as first-line treatment for PD-L1 positive advanced NSCLC: Results from the randomized, controlled, registrational Phase III OptiTROP-Lung05 study (Abstract #8506) * Efficacy and safety of lunbotinib fumarate (A...
2026-05-22 08:00
7764
Formosa Pharmaceuticals Announces Presentation of TSY-310 at the 2026 ASCO Annual Meeting
TAIPEI, May 21, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. announces that its abstract highlighting the differentiated binding profile and preclinical efficacy ofTSY-310, a novel bispecific antibody-drug conjugate (ADC), has been selected for presentation at the American Society of Clinic...
2026-05-22 05:34
4745
Kelun-Biotech Announces Phase III Trial of Sacituzumab Tirumotecan (sac-TMT) versus Chemotherapy as First‑line Treatment for Advanced TNBC Met Primary Endpoint of PFS
CHENGDU, China, May 21, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study (OptiTROP-Breast03) of the Company's tropho...
2026-05-21 22:08
8833
Guangzhou Lupeng/Newave Pharmaceutical Inc. Enrolled the First Patient in the Global Phase 3 ROCKET-CLL Trial Evaluating Rocbrutinib (LP-168) vs. Pirtobrutinib in R/R CLL/SLL
Head-to-Head Study Highlights Rocbrutinib as the World's First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations GUANGZHOU, China and SAN FRANCISCO, May 21, 2026 /PRNewswire/ -- Lupeng Pharmaceutical Ltd, a global clinical-stage biopharmaceu...
2026-05-21 22:00
6662
Hyundai Bioscience Discloses XAFTY®'s IC50 Data for Ebola--"Secured Scientific Evidence for Immediate Treatment"
* Ebola IC50 (0.125μM)—Strong inhibition at less than half the concentration of the clinically-tested COVID-19 (0.28μM). * Clinical safety confirmed through COVID-19 and Dengue clinical trials. * Class-wide efficacy proven by accumulated research data for Hantavirus treatment. * Davey Smit...
2026-05-21 08:38
5141
DeepQure Announces Robust 3-Month Results from HERO-HTN Clinical Study at EuroPCR 2026
PARIS, May 20, 2026 /PRNewswire/ -- DeepQure, a clinical-stage medical device company, today announced robust 3-month clinical data from its HERO-HTN-FIH study during a featured presentation at EuroPCR 2026. The interim results demonstrate that the HyperQure™ extravascular renal denervation (RDN)...
2026-05-20 22:00
6107
Sanyou Bio Launches SAI-DA 1.0, the AI-Drug Accelerator
SHANGHAI, May 20, 2026 /PRNewswire/ -- Sanyou Bio today announced the launch of SAI-DA 1.0 (Sanyou AI-Drug Accelerator). The platform builds on the company's AI-STAL (AI Super-Trillion Antibody Library), which serves as a vast molecular resource bank of super-trillion-scale molecules, SAI-DA 1.0 ...
2026-05-20 22:00
5370
METiS TechBio to Present Late-Breaking Data on Near-Complete Cardiomyocyte Delivery at CRS 2026
BEIJING, HANGZHOU, China and CAMBRIDGE, Mass., May 20, 2026 /PRNewswire/ -- METiS TechBio (7666.HK), a global leader in AI-powered drug delivery innovation, today announced that new preclinical data from its heart-targeted LNP program has been selected for a Late-Breaking oral presentation at the...
2026-05-20 18:57
5524
WuXi Biologics Hosts Third CRDMO Day in Japan, Accelerating Biopharma Innovation from IND to Commercialization
TOKYO, May 20, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), recently hosted its third CRDMO Day in Tokyo, bringing together senior leaders and experts from Japan's biopharmaceutical industry, exchanging the ...
2026-05-20 13:44
7057
Week's Top Stories
Most Reposted
Visa Reimagines Visa Infinite for Asia Pacific's Modern Affluent
[Picked up by 305 media titles]
2026-07-16 10:00
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
[Picked up by 295 media titles]
2026-07-20 15:00
Singapore Tourism Board and Traveloka Renew Partnership to Welcome More Southeast Asian and Australian Travellers to Singapore
[Picked up by 291 media titles]
2026-07-17 18:18
Klook signs an expanded two-year partnership with Korea Tourism Organization
[Picked up by 288 media titles]
2026-07-16 17:49
Omni HR Launches Native MCP Integration, Connecting AI Assistants to Live HR Data
[Picked up by 286 media titles]
2026-07-20 11:00
Most Read
Visa Reimagines Visa Infinite for Asia Pacific's Modern Affluent
2026-07-16 10:00
18906
Klook signs an expanded two-year partnership with Korea Tourism Organization
2026-07-16 17:49
14121